LAG3 and melanoma: In a randomized trial, the phase II/III study revealed that the anti-LAG-3 therapeutic relatlimab, when used alongside nivolumab (anti-PD-1), led to a 12-month progression-free survival (PFS) rate of 47.7% in melanoma patients.